EP0423236A1 - Peptides caracterises par une selectivite exceptionnelle vis-a-vis des recepteurs opioides - Google Patents

Peptides caracterises par une selectivite exceptionnelle vis-a-vis des recepteurs opioides

Info

Publication number
EP0423236A1
EP0423236A1 EP89908922A EP89908922A EP0423236A1 EP 0423236 A1 EP0423236 A1 EP 0423236A1 EP 89908922 A EP89908922 A EP 89908922A EP 89908922 A EP89908922 A EP 89908922A EP 0423236 A1 EP0423236 A1 EP 0423236A1
Authority
EP
European Patent Office
Prior art keywords
polypeptide according
hydrogen
dpdpe
polypeptide
lower alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP89908922A
Other languages
German (de)
English (en)
Other versions
EP0423236A4 (en
Inventor
Victor Joseph Hruby
Geza Toth
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Research Corp Technologies Inc
Original Assignee
Research Corp Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Research Corp Technologies Inc filed Critical Research Corp Technologies Inc
Publication of EP0423236A1 publication Critical patent/EP0423236A1/fr
Publication of EP0423236A4 publication Critical patent/EP0423236A4/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C07K14/70—Enkephalins
    • C07K14/702—Enkephalins with at least 1 amino acid in D-form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • This invention relates to compounds that are rigid analogs of enkephalins having improved delta receptor specificity. This invention also relates to a method
  • Opioid analgesics are narcotics useful for treating moderate to severe pain and also useful in the treatment of diarrhea and coughing. Morphine/ a plant alkaloid,
  • Naturally occurring opiates are found in the human brain/ as well as in various tissues of lower animals. Naturally occurring enkephalin is
  • endorphins class of opioid peptides known as "endorphins.”
  • opioid receptor that entity, on a cell, which recognizes and binds a chemical substance.
  • An opiate receptor therefore, recognizes and binds an opiate drug.
  • opioid drugs may act to initiate or block various biochemical and physiological sequences. Such initiation or blockage is often referred to as transduction.
  • opioid receptors which are affected by opioids.
  • the major known types of opioid receptors are the mu, delta and kappa
  • mu receptors For examples, mu receptors
  • Kappa receptors mediate sedation. While delta receptors are believed also to produce analgesia, as above described, it is believed that they do not inhibit intestinal transit in the manner associated with mu receptors.
  • the biological activity and binding properties of opioids are directly linked to the opioid structure.
  • Opioid compounds structurally capable of binding at receptor sites may have a variety of biological effects, all of which are useful in attaining a variety of pharmacological and therapeutic effects.
  • Certain opioids known as
  • agonists inhibit certain electrically stimulated outputs of neurotransmitters in tissues containing receptors, and, for example, may inhibit electrically stimulated contractions and other responses.
  • Morphine is an agonist and acts to inhibit transmissions associated with pain and gastrointestinal tract contractions. It is also known that other substances, known as “antagonists”, prevent the action of agonists by binding to the receptor without inhibiting electrically stimulated outputs in the manner associated with agonists.
  • antagonists prevent the action of agonists by binding to the receptor without inhibiting electrically stimulated outputs in the manner associated with agonists.
  • Naloxone is an antagonist and acts to prevent an agonist from binding at the receptor. Additionally, some substances act as either partial agonists or partial antagonists.
  • Naturally occurring opioid analgesics known as endorphins, particularly enkephalins, have been extensively studied. The research began with the isolation of naturally occurring enkephalin, which is a mixture of methionine
  • Gly stands for glycine
  • Leu stands for leucine
  • Teyr stands for tyrosine
  • Pen stands for penicillamine
  • Cys stands for cysteine
  • Phe stands for phenylalanine
  • Thr stands for threonine
  • Metal stands for methionine.
  • H 2 N-Tyr-Gly-Gly- Phe-Pen-OH is written as ([Pen 5 ] enkephalin) signifying that penicillamine has been substituted for the leucine or
  • amino acids normally forming the fifth amino acid from the amino terminus in enkephalin. Additionally, amino acids may exist as stereoisomers in both L and D configurations.
  • enkephalin-like peptides are known not to cross the blood brain barrier easily. They are, however, known to cross the placental barrier and cannot, therefore, be used as analgesics during pregnancy and in childbirth without affecting the unborn child.
  • Each enkephalin analog has fairly selective effects in different systems. Specifically, it has been found that different enkephalin analogs bind to differen opioid receptors. However, it has been difficult to study th role of each receptor type or to induce selectively the pharmacological and therapeutic effects associated with each receptor type because the enkephalin analogs, to date, have not had a high degree of selectivity for a single-receptor. type.
  • constraints include alpha or N-methylation of the peptide backbone or cyclization.
  • R 1 is hydrogen, lower alkyl, allyl, 2-isopentenyl, 3-isopentenyl, cyclopropylmethyl, cyclobutylmethyl, phenethyl or arginyl;
  • R 2 is hydrogen or lower alkyl
  • R 3 is hydrogen or lower alkyl
  • R 4 is hydrogen, hydroxymethyl, carbo (lower) alkoxy, carbamyl or carboxy;
  • X is hydrogen, chloro, fluoro, bromo or iodo, the linear precursors thereof or a pharmaceutically acceptable salt thereof.
  • the compounds disclosed by Sarantakis are said to exert an analgesic effect in warm-blooded animals when peripherally administered.
  • the Sarantakis compounds are not disclosed as specific to any receptor type.
  • few enkephalin analogs have been developed which react specifically with the delta receptor.
  • R 1 and R 2 which may be the same or different, are hydrogen, methyl or lower alkyl
  • R 3 and R 4 which may be the same or different, are hydrogen, methyl or lower alkyl, provided R 1 , R 2 , R 3 and R 4 may not all be hydrogen when both n and m are 0; R 5 is hydrogen, L-tyrosine, D-tyrosine, or
  • R 6 is a substituted or unsubstituted aromatic
  • R 7 is hydrogen or methyl
  • R 8 is carboxylate, carboxamide or amino acid
  • X and Y are hydrogen or methyl; and n and m are each 0 or 1.
  • the compounds therein are said to possess either agonist or antagonist activity to opioid receptors, and may be used to induce pharmacological or thearapeutic effects, including analgesia on humans and other animals
  • the present invention provides novel compounds which are capable of binding with enhanced specificity to the delta receptor (hereinafter sometimes referred to as "delta receptor specificity").
  • delta receptor specificity The compounds are a series of cyclic,
  • novel compounds include those which function either as agonists or antagonists and may be used to induce pharmacological or therapeutic effects corresponding to agonist or antagonist activity in humans and other animals.
  • delta receptor agonists are delta receptor agonists and may be used to induce analgesia in humans and lower animals without significant involvement of mu receptors and their associated side effects.
  • delta receptor agonists may be used to induce analgesia in humans and lower animals without significant involvement of mu receptors and their associated side effects.
  • antagonists may be used to block the action of delta receptor agonists prepared in accordance with the present invention when necessary or desirable or may be used to induce other pharmacological and therapeutic effects of opioid antagonists, such as in treatment of Alzheimer's Disease.
  • R 1 , R 2 , R 7 and R 8 are each independently hydrogen or lower alkyl
  • R 3 and R 4 are each independently hydrogen or lower alkyl
  • R 5 and R 6 are each independently hydrogen or lower alkyl, provided that at least one of R 3 , R 4 , R 5 and R 6 is other than hydrogen when both n and p are zero;
  • R 9 is lower alkyl or hydrogen
  • R 10 is hydroxy, lower alkoxy, amino, loweralkylamino, lower dialkylamino;
  • R 11 , R 12 and R 13 are each independently hydrogen or er alkyl
  • R 14 is hydrogen, lower alkyl or lower alkanoyl
  • B is Gly or a chemical bond
  • X is hydrogen, lower alkyl, lower alkenyl, lower alkynyl, carboxy, lower carbalkoxy, carbamoyl, loweralkylamino carbonyl, lowerdialkylamino carbonyl, lower alkoxy, amino, halo, nitro, cyano, lower alkanoyl or formyl;
  • Y is hydrogen, lower alkyl, lower alkenyl, lower alkynyl, carboxy, lower carbalkoxy, carbamoyl, lower
  • alkylamino carbonyl lowerdialkylamino carbonyl
  • n, p and q are each independently 0, 1 or 2
  • lower alkyl groups either singly or in combination with other groups contain up to 6 carbon atoms which may be in the normal or branched configuration and include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, amyl, pentyl, hexyl and the like.
  • the preferred alkyl groups contain 1 to 3 carbon atoms.
  • alkyl group is methyl.
  • Lower alkenyl and alkynyl groups contain from 2 to 6 carbon atoms which may in the normal or branched
  • Lower alkenyl groups include ethenyl
  • Lower alkynyl groups include ethynyl, propynyl, butynyl, isobutynyl, pentynyl, isopentynyl, and the like.
  • Halo as used herein, is bromo, fluoro, iodo and chloro.
  • Alkanoyl as used herein is a lower alkyl group containing a carbonyl group on the main chain.
  • the carbonyl group may be at the end or in the middle of said chain.
  • the preferred alkanoyl group is acetyl.
  • R 1 , R 2 , R 7 and R 8 may be the same or different.
  • the preferred values of each of R 1 , R 2 , R 7 and R 8 are
  • R 1 , R 2 , R 7 and R 8 are hydrogen.
  • R 3 , R 4 , R 5 and R 6 are hydrogen or methyl. It is especially preferred that R 3 , R 4 , R 7 and R 8 are all methyl.
  • R 9 are hydrogen or methyl.
  • R 10 is hydroxy
  • R 11 is hydrogen or methyl.
  • Hydrogen is especially preferred.
  • Hydrogen or methyl is preferred for R 12 . Hydrogen is especially preferred.
  • R 13 is hydrogen or methyl. It is preferred that R 14 is hydrogen or acetyl.
  • B is Gly.
  • Preferred values of X include methoxy, iodo, bromo, amino, chloro, nitro and hydrogen.
  • Y are iodo, chloro, bromo, methoxy, nitro and hydrogen.
  • a preferred embodiment of the present invention has the formula:
  • R 3 , R 4 , R 5 , R 6 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , B, X and Y are as defined heretofore.
  • X is methoxy, iodo, bromo, chloro, nitro, amino or hydrogen
  • Y is iodo, chloro, bromo, methoxy, nitro or hydrogen
  • R 13 is hydrogen or methyl
  • R 14 is hydrogen, lower alkanoyl or alkyl
  • residues, except Gly are in the L-configuration except for the penicillamine at position 2 and 5 and the amino acid in position 4 (which may be phenylalanine or derivatives thereof or homophenylalanine or derivatives thereof, etc.).
  • the amino acid in position 4 may be in either the D or L configuration.
  • the penicillamine in position 2 is in the D-configuration while the penicillamine in position 5 can be D or L. It is preferred that the pencillamine in position 5 be in the
  • Preferred species of the present invention are: [p-Cl-Phe 4 ]DPDPE
  • Tyr is" the first amino acid
  • pencillamine is second, glycine is third, phenylalanine is fourth and pencillamine is fifth.
  • the compounds of the present invention include both agonists and antagonists.
  • the present invention is also directed to a process for inducing analgesia in human and lower animals by
  • the compounds which are agonists may be useful as analgesics without producing the undesirable side effects associated with previously known opioids. It is believed that the agonists of the present invention are useful in pregnancy and child birth because they will not cross the placental barrier, and therefore, they will not harm the unborn child.
  • the antagonist compounds may also be useful in the treatment of schizophrenia, Alzheimer's disease, as well as in the treatment of respiratory and cardiovascular functions.
  • polypeptides of the present invention are cyclic opioid compounds having greatly
  • Such geminal dialkyl groups combined with the S-S bridge, produce enkephalin analogs which are conformationall stable.
  • these compounds possess the three dimensional conformation required for activity at the delta receptor and at the same time exclude the optimal conformation required for activity at the mu receptor.
  • half-cysteine preferably the D-isomer.
  • half-penicillamine enkephalin analog can have as much as a six hundred fold increased selectivity in delta receptor specific assays, compared to activity in mu receptor specific assays.
  • the geminal dialkyl substituted compounds of the present invention also display increased delta receptor specificity in rat brain binding assays.
  • a unique feature of some of the preferred enkephalin analogs of the present invention is the incorporation of a half-penicillamine amino acid residue into the two and/or five position of the enkephalin.
  • Penicillamine is
  • beta,beta-dimethylcysteine These compounds share the common feature of having at least one pair of geminal dialkyl groups in the ring. These dialkyl groups impose a particularly high degree of conformational restriction and steric hindrance resulting in particularly high delta receptor specificity. It is also believed that unfavorable steric and/or
  • an agonist will inhibit an electrically stimulated contraction in smooth muscle and an antagonist will reverse the inhibition caused by an agonist.
  • Whether a particular compound of the present invention is an agonist, partial agonist, antagonist or partial antagonist can be determined by routine experimentation by those skilled in the art in light of the teachings contained herein. However, the compounds of the present invention are believed to share the property of having enhanced specificity for the delta receptor.
  • L-homocysteine may be substituted for pencillamine, or cysteine in the two or five position of the polypeptides of the present invention.
  • the compounds of the present invention can be prepared by art recognized techniques. An examplary procedure is as follows.
  • disulfide bond can be formed by dissolving the linear peptide in
  • polypeptide of Formula VI can be prepared by art recognized techniques .
  • the polypeptide of Formula VI can be prepared under peptide forming conditions from the amino acid moieties depicted hereinbelow:
  • Z is an amino protecting group and A is a carboxy protecting group.
  • A is a carboxy protecting group.
  • the growing polypeptide chain is removed by techniques
  • A is benzyloxy carbonyl
  • Z is benzyloxy carbonyl
  • it can be removed by catalytic hydrogenation or by acid reagents, such as HBr/HOAc, HF/Pyr, and the like.
  • Coupling of the compound in each step of the Scheme employs established techniques in peptide chemistry.
  • One such technique uses dicyclohexylcarbodimide (DCC) as the coupling agent.
  • DCC dicyclohexylcarbodimide
  • the DCC method may be employed with or without
  • additives such as 4-dimethylaminopyridine, HOBt or copper
  • the DCC coupling reaction generally proceeds at room temperature, however, it may be carried out from about -20o to 50oC. in a variety of solvents inert to the reactants.
  • suitable solvents include, but are not limited to, N,N-dimethylformamide, methylene chloride, toluene and the like.
  • the reaction is carried out under an inert atmosphere such as argon or nitrogen.” Coupling usually is complete within 2 hours but may take as long as 24 hours depending on reactants .
  • X and Y be present on the amino acids prior to the coupling.
  • X and Y can be added to the appropriate amino acid moieties by techniques known to one skilled in the art, such as electrophilic aromatic addition, e.g, nitration, halogenation, Friedel Crafts alkylation and acylation, and the like.
  • electrophilic aromatic addition e.g, nitration, halogenation, Friedel Crafts alkylation and acylation, and the like.
  • the p-nitro- ⁇ - methylphenylalanine isomers may be prepared by nitration of erythro and threo ⁇ -MePhe, which can be synthesized and separted by Kataoka, et al., Bulletin Chem. Soc. of Japan, 49, 1081-1084 (1976), which is incorporated herein by reference.
  • polypeptides be synthesized by solid phase peptide synthesis. Said synthesis takes place on a solid phase matrix, such as chloromethylated polystyrene crosslinked with 1-2% divinylbenzene.
  • a solid phase matrix such as chloromethylated polystyrene crosslinked with 1-2% divinylbenzene.
  • the N-protected amino acid at the C-terminal end, i.e., Z-V can be attached to the resin using the procedure disclosed by Gisin, Helv. Chim, Acta, 56, 1476 (1973), which is specifically incorporated herein by reference.
  • the Z-V-resin is placed into a solid phase peptide synthesis reaction vessel and Z-IV, Z-III, Z-II and Z-I are added sequentially under solid phase peptide synthesis
  • deprotection can be accomplished by trifluoroacetic acid and anisole in dichloromethane. This is followed by neutralization of the resulting peptide with 10% diisopropylethylamine. This peptide is then coupled with another N-protected amino acid moiety, and the process is continued until the desired polypeptide of Formula VI is synthesized.
  • the polypeptide may be deprotected by techniques known to one skilled in the art.
  • the peptide resin may be washed with dichloromethane, ethanol and DCM and dried.
  • the peptide resins then are cleaved by liquid HF in the presence of anisole. The solvents are evaporated off, the dried product is washed with ethyl ether and the peptide is
  • the resulting polypeptide where R 10 is hydroxy can then be transformed to the other polypeptides of Formula VI, wherein R 10 is amino, alkoxy, alkylamino or dialkylamino by techniques known to one skilled in the art.
  • the polypeptides wherein R 10 is alkoxy can be formed under Fischer esterification conditions from the corresponding acid.
  • R 10 is methoxy or ethoxy
  • diazomethane or diazoethane, respectively, synthesized in situ can be used.
  • Formation of compounds wherein R 10 is amino, alkylamino or dialkylamino can be formed by reacting the ester with ammonia, N-alkylamine or N, N-dialkylamine to form the corresponding unsubstituted, N-substituted or N,N,-disubstituted amide.
  • Analytical HPLC can be performed using Vydac 218TP1010 C18 column (25 cm ⁇ 1 cm) under isocratic conditions using 25% acetonitrile in 0.1%.
  • peptides (ca. 0.5 mg) can be hydrolyzed with
  • the present new compounds contain basic nirrogen an can form salts with acids. All such acid salts are
  • salts with pharmaceutically acceptable acids such as
  • quaternary salts can be formed using standard techniques of alkylation employing, for example, hydrocarbyl halides or sulfates such as methyl, ethyl, benzyl, propyl or allyl halides or sulfates.
  • the compounds of the present invention can be administered to the host in a variety of forms adapted to the chosen route of administration, i.e., orally, intravenously, intramuscularly or subcutaneous routes.
  • the active compound may be orally administered, for example, with an inert diluent or with an assimilable edible carrier, or it may be enclosed in hard or soft shell gelatin capsules, or it may be compressed into tablets, or it may be incorporated directly with the food of the diet.
  • the active compound may be orally administered, for example, with an inert diluent or with an assimilable edible carrier, or it may be enclosed in hard or soft shell gelatin capsules, or it may be compressed into tablets, or it may be incorporated directly with the food of the diet.
  • the active compound may be
  • compositions and preparations should contain at least 0.1% of active compound.
  • the percentage of the compositions and preparations may, of course, be varied and may conveniently be between about 2 to about 60% of the weight of the unit.
  • the amount of active compound in such therapeutically useful compositions is such that a suitable dosage will be obtained.
  • Compositions or preparations according to the present invention are prepared so that an oral dosage unit form contains an amount of active compound ranging from about 1 ug/kg of body weight to about 1000 ug/kg of body weight. Preferred dosage of active
  • the tablets, troches, pills, capsules and the like may also contain the following: A binder such as gum
  • tragacanth acacia, corn starch or gelatin
  • excipients such as dicalcium phosphate
  • a disintegrating agent such as corn starch, potato starch, alginic acid and the like
  • a lubricant such as magnesium stearate
  • a sweetening agent such as sucrose, lactose or saccharin or a flavoring agent such as peppermint, oil of wintergreen, or cherry flavoring may be added.
  • a sweetening agent such as sucrose, lactose or saccharin or a flavoring agent such as peppermint, oil of wintergreen, or cherry flavoring may be added.
  • the dosage unit form is a capsule, it may
  • a liquid carrier may contain, in addition to materials of the above type, a liquid carrier.
  • Various other materials may be present as coatings or to otherwise modify the physical form of the dosage unit.
  • tablets, pills, or capsules may be coated with shellac, sugar or both.
  • a syrup or elixir may contain the active compound, sucrose as a sweetening agent, methyl and propylparabens as preservatives, a dye and flavoring such as cherry or orange flavor.
  • any material used in preparing any dosage unit form should be pharmaceutically pure and substantially non-toxic in the amounts employed.
  • the active compound may be incorporated into
  • sustained-release preparations and formulations are provided.
  • the active compound may also be administered.
  • Solutions of the active compound as a free base or pharmacologically acceptable salt can be prepared in water suitably mixed with a surfactant such as hydroxypropylcellulose.
  • Dispersions can also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.
  • the pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile
  • the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, and vegetable oils.
  • the proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size, in the case of dispersions, and by the use of surfactants.
  • micro-organisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like.
  • isotonic agents for example, sugars or sodium chloride.
  • Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminum monostearate and gelatin.
  • Sterile injectable solutions are prepared by:
  • dispersions are prepared by
  • a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above.
  • the preferred methods of preparation are vacuum drying and the freeze-drying technique which yield a powder of the active ingredient plus any additional desired ingredient from previously sterile-filtered solution thereof.
  • DPDPE. 1 enkephalin
  • N -Boc-(S,R) and (R,S)p-NO 2 - ⁇ -MePhe-OH racemic amino acid (Mp : 84oC), N ⁇ -Boc-Gly-OH N ⁇ -Boc-S-pMB-D-Pen-OH and N ⁇ -Boc-Tyr-OH were coupled to the growing peptide chain following the protocol outlined above.
  • the peptide was cleaved from the resin by HF, the cyclization of linear
  • diastereomer peptide was performed by semipreparative RP-HPLC using Vydac 218TP1010 C18 column (25 cm ⁇ 1 cm); combining the isocratic and gradient chromatography. Conditions were:
  • the peptide from first peak was the (S,R) [p-NO 2 - ⁇ -MePhe 4 ]
  • the first peak was polymer
  • the second peak was the [3'-I- Tyr 1 ]DPDPE.
  • FABMS [M+1] + 772, found 772.
  • reaction mixture was determined by HPLC using Vydac 218TP1010 C18 column with linear gradient elution of 20-40% CH 3 CN in aqueous 0.1% trifluoroacetic acid, 1% min at a flow rate of 3 mL/min.
  • [3'-OCH 3 Tyr 1 ]DPDPE The title compound was prepared as for [3'-NO 2 Tyr 1 ]DPDPE by SPPS except that N ⁇ -Boc-3'-OCH 3 Tyr-OH was added to the growing peptide chain instead of N ⁇ -Boc-3'-NO-Tyr -OH. The work up and purification were the same procedure as for [p-FPhe 4 ]DPDPE.
  • HPLC: K' 1.05; FABMS: (M+1) + 676, found 676.
  • the compounds of the present invention were tested for their relative activites in the guinea pig ileum
  • GPI mouse vas deferens
  • MVD mouse vas deferens
  • GPI and MVD Bioassays Electrically induced smooth muscle contractions of mouse vas deferens and strips of guinea pig ileum longitudinal muscle-myenteric plexus were used as a bioassay.
  • Tissues came from male Hartley guinea pigs weighing 150-400 grams and male ICR mice weighing 25-30 grams.
  • the tissues were tied to gold chains with suture silk, suspended in 20 mL baths containing 37oC oxygenated (95% 0, 5% CO 2 ) Krebs-dicarbonate solution (magnesium-free for the MVD) and allowed to equilibrate for 15 min.
  • the tissues were then stretched to 1 g tension (0.5 g for MVD) and allowed to equilibrate for 15 min.
  • the tissues were stimulated transmurally between platinum plate electrodes at 0.1 Hz, 0.4 msec pulses (2.0 msec pulses for MVD) and supramaximal
  • the GPI preparation has been shown to contain primarily mu type opiate receptors and the MVD preparation primarily delta type opiate receptors.
  • comparisons of IC.. Q value in these two assay systems, as shown in Table II provide a measure of the receptor specificity of the tested analogs.
  • the results shown in Table II clearly indicate the high delta receptor selectivity of these analogs.
  • Radioreceptor binding assay This assay tests the ability of the enkephalin analogs to inhibit opiate receptor binding and displace tritiated
  • the data were analyzed by using nonlinear least-square regression analysis on the Apple II computer.
  • the claimed delta receptor agonist compounds are believed to be useful in the treatment of pain without the undesirable side effects associated with previously known opiates.
  • Compounds according to the present invention having antagonist activity are believed to behave in a manner similar to naloxone and, thereby, are believed to be useful in those areas where narcotic antagonists have been useful in the prior art, including the treatment of Alzheimer's disease. See generally, Reisberg, B., et al. New Eng. J. Med., Vol. 308: 12, 721-722 (1983), which is specifically incorporated herein by reference.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Polypeptide de formule (I) ayant une activité agoniste ou antagoniste vis-à-vis des récepteurs opioïdes delta. Ces composés peuvent être employés pour produire des effets pharmacologiques ou thérapeutiques, y compris une analgésie, chez l'enfant.
EP19890908922 1988-07-06 1989-07-06 Peptides with extraordinary opioid receptor selectivity Ceased EP0423236A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21674588A 1988-07-06 1988-07-06
US216745 1988-07-06

Publications (2)

Publication Number Publication Date
EP0423236A1 true EP0423236A1 (fr) 1991-04-24
EP0423236A4 EP0423236A4 (en) 1991-09-25

Family

ID=22808339

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19890908922 Ceased EP0423236A4 (en) 1988-07-06 1989-07-06 Peptides with extraordinary opioid receptor selectivity

Country Status (3)

Country Link
EP (1) EP0423236A4 (fr)
JP (1) JPH03505734A (fr)
WO (1) WO1990000564A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5169833A (en) * 1989-12-15 1992-12-08 G. D. Searle & Co. Substituted cyclic pentapeptides
US5216124A (en) * 1989-12-15 1993-06-01 G. D. Searle & Co. Substituted cyclic tetrapeptides
WO1991009051A1 (fr) * 1989-12-15 1991-06-27 G.D. Searle & Co. Tetrapeptides cycliques substitues d'acide penicillanique
FR2697850B1 (fr) * 1992-11-10 1994-12-02 Univ Pasteur Nouveaux polypeptides ayant une activité de récepteur opioïde, acides nucléiques codant pour ces polypeptides et utilisations.
US5780589A (en) * 1994-11-30 1998-07-14 The United States Of America As Represented By The Department Of Health And Human Services Ultraselective opioidmimetic peptides and pharmacological and therapeutic uses thereof
WO2010022249A2 (fr) 2008-08-20 2010-02-25 Ensemble Discovery Corporation Composés destinés à l’inhibition du facteur de nécrose tumorale alpha

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4148786A (en) * 1978-06-26 1979-04-10 American Home Products Corporation Analgesic polypeptide
US4304715A (en) * 1979-06-08 1981-12-08 Derek Hudson Enkephalin analogues
US4518711A (en) * 1983-05-16 1985-05-21 Gibson-Stephens Institute Conformationally constrained cyclic enkephalin analogs with delta receptor specificity

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Peptides, Proc. 9th American Peptide Symposium, 1985, pages 496-497; Ed. C.M. DEBER et al.; Pierce Chemical Company, P.D. GESELLCHEN et al.: "Opioid receptor binding affinity and efficacy of metkephamid analogs modified at the phenylalanine residue", the whole document. *
See also references of WO9000564A1 *

Also Published As

Publication number Publication date
WO1990000564A1 (fr) 1990-01-25
JPH03505734A (ja) 1991-12-12
EP0423236A4 (en) 1991-09-25

Similar Documents

Publication Publication Date Title
US4684620A (en) Cyclic polypeptides having mu-receptor specificity
US4518711A (en) Conformationally constrained cyclic enkephalin analogs with delta receptor specificity
EP0350221B1 (fr) Analogues de dermorphine, leur méthode de préparation, compositions pharmaceutiques et méthodes de traitement thérapeutiques les utilisant
Hansen Jr et al. Systemic analgesic activity and. delta.-opioid selectivity in [2, 6-dimethyl-Tyr1, D-Pen2, D-Pen5] enkephalin
Toth et al. Ring substituted and other conformationally constrained tyrosine analogs of [cyclic][D-Pen2, D-Pen5] enkephalin with. delta.-opioid receptor selectivity
Toth et al. [Cyclic][D-Pen2, D-Pen5] enkephalin analogs with increased affinity and selectivity for. delta.-opioid receptors
US4322339A (en) Pharmacologically active peptides
US4407746A (en) Cyclohexyl and phenyl substituted enkephalins
HU185320B (en) Process for producing biologically active encephaline analogous compounds
EP0486520B1 (fr) Analogues de dynorphine specifiques sur des recepteurs d'opioide de kappa
EP0423236A1 (fr) Peptides caracterises par une selectivite exceptionnelle vis-a-vis des recepteurs opioides
Hocart et al. Effect of the CH2NH and CH2NAc peptide bond isosteres on the antagonistic and histamine releasing activities of a luteinizing hormone-releasing hormone analog
HU186375B (en) Process for the preparation of biologically active encephalina derivatives
Chao et al. Preparation and use of the 4-[1-[N-(9-fluorenylmethyloxycarbonyl) amino]-2-(trimethylsilyl) ethyl] phenoxyacetic acid linkage agent for solid-phase synthesis of C-terminal peptide amides: improved yields of tryptophan-containing peptides
US4468383A (en) Dimeric enkephalins
Wan et al. Inhibitors of the luteinizing hormone-releasing hormone based upon modifications in the 2, 3, and 6 positions
JP2781782B2 (ja) 新規ペプチド
Salvadori et al. Synthesis and pharmacological activity of partially modified retro-inverso dermorphin tetrapeptides
JPS59101451A (ja) 薬理学的に活性なペプチド
US4450155A (en) Analgesic dipeptide amides and method of use and compositions thereof
EP0008196B1 (fr) Pentapeptides, procédés pour leur préparation, les intermédiaires utilisés dans ces procédés, emploi dans des compositions pharmaceutiques, et les compositions les contenant
US4144228A (en) Methionine5 -enkephalin sulfoxides and sulfones
WO1991008759A1 (fr) Pentapeptides d'acide penicillanique cycliques substitues par un alkyle
US4216127A (en) Enkephalin analogues
EP0115850A2 (fr) Peptides, leur procédé de préparation et composition pharmaceutique contenant lesdits peptides

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19910107

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

A4 Supplementary search report drawn up and despatched

Effective date: 19910806

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: RESEARCH CORPORATION TECHNOLOGIES, INC.

17Q First examination report despatched

Effective date: 19940307

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 19970203